Sanofi positions France at centre of strategy with investment

Sanofi has detailed plans on how it will make significant investments in France to increase its vaccines research and production capacities and contribute in responding to future pandemic risks.

Sanofi will invest €610 million to create a new production site and research centre in France with both dedicated to vaccines.

“By investing in a new industrial site and a R&D centre, Sanofi positions France at the core of its strategy, aiming to make France a world-class centre of excellence in vaccine research and production,” said CEO Paul Hudson.

Sanofi will invest in vaccine production in France and create its Evolutive Vaccine Facility (EVF) in Neuville sur Saône. This state-of-the-art industrial site will utilise the latest innovative vaccine production technologies.

The project represents an investment of €490 million over a five-year period, and is expected to create 200 new jobs. Sanofi’s investment has been made possible thanks to the support and the close collaboration with French authorities over the last few months.

The building of this plant will enable Sanofi Pasteur – Sanofi’s global entity dedicated to vaccines – to be the first pharmaceutical manufacturer to benefit from such an industrial tool and to secure vaccine supplies in the event of new pandemics.

EVF is a new type of factory designed around a central unit housing several fully digital production modules that make it possible to produce three to four vaccines simultaneously, versus only one in current industrial sites. This modularity will make it possible to prioritise the production of a specific vaccine in a more timely manner based on public health issues.

Sanofi has also committed to investing €120 million to create a new R&D centre in France at the Sanofi Pasteur site in Marcy-l’Etoile to develop future vaccines.

This state-of-the-art digital facility will house highly specialised laboratories that will enable the development of vaccines against emerging diseases and pandemic risks.

The facility will become a world reference for pre-clinical research and pharmaceutical and clinical development. Sanofi expresses its gratitude to the Auvergne-Rhône-Alpes French region for its support in this project.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Avalon GloboCare & BOKU to advance intranasal & oral COVID-19 vaccine candidate

Avalon GloboCare, a New Jersey-based clinical-stage global developer of cell-based technologies and therapeutics, has partnered with the University of Natural Resources and Life Sciences...

Sanofi & Translate Bio expand collaboration to develop mRNA vaccines

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, are expanding their existing 2018...

Sarepta & Codiak to research, develop exosome-based therapeutics

Precision medicine specialist, Sarepta Therapeutics, and Codiak BioSciences, a company at the forefront of advancing engineered exosomes as a new class of biologic medicines,...

Gilead acquires equity interest in pioneering immunotherapy company

Gilead Sciences is acquiring a 49.9% equity interest in Pionyr Immunotherapeutics, a privately held San Fran company developing first-in-class cancer immunotherapies. The acquisition – for...

New class of precision medicine strips cancer of its DNA defences

A new precision medicine targeting cancer’s ability to repair its DNA has shown promising results in the first clinical trial of the drug class. The...

Related news

Pharma industry invests £381m in UK R&D activities

The pharmaceutical industry has invested £381.2 million on R&D activities in the UK during 2019, up from £377.3 million in 2018, according to new...

Avalon GloboCare & BOKU to advance intranasal & oral COVID-19 vaccine candidate

Avalon GloboCare, a New Jersey-based clinical-stage global developer of cell-based technologies and therapeutics, has partnered with the University of Natural Resources and Life Sciences...

Sanofi & Translate Bio expand collaboration to develop mRNA vaccines

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, are expanding their existing 2018...

Sarepta & Codiak to research, develop exosome-based therapeutics

Precision medicine specialist, Sarepta Therapeutics, and Codiak BioSciences, a company at the forefront of advancing engineered exosomes as a new class of biologic medicines,...